Compugen (NASDAQ:CGEN – Get Rating) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01, MarketWatch Earnings reports. During the same period last year, the company earned ($0.11) EPS. Compugen Trading Up 10.0 % Shares of Compugen stock opened […]
Stockman Wealth Management Inc. acquired a new stake in Compugen Ltd. (NASDAQ:CGEN – Get Rating) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 70,800 shares of the biotechnology company’s stock, valued at approximately $51,000. Stockman Wealth Management Inc. owned 0.08% of Compugen […]
Compugen Ltd. (NASDAQ:CGEN – Get Rating) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 1,890,000 shares, a decline of 5.5% from the March 15th total of 2,000,000 shares. Based on an average daily trading volume, of 429,600 shares, the days-to-cover ratio is […]
Graphite Bio (NASDAQ:GRPH – Get Rating) and Compugen (NASDAQ:CGEN – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Volatility and Risk Graphite Bio has a beta of 0.01, […]
Antonetti Capital Management LLC raised its stake in shares of Compugen Ltd. (NASDAQ:CGEN – Get Rating) by 12.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 583,277 shares of the biotechnology company’s stock after buying an additional […]